» Articles » PMID: 16760251

Interlaced X-ray Microplanar Beams: a Radiosurgery Approach with Clinical Potential

Overview
Specialty Science
Date 2006 Jun 9
PMID 16760251
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Studies have shown that x-rays delivered as arrays of parallel microplanar beams (microbeams), 25- to 90-microm thick and spaced 100-300 microm on-center, respectively, spare normal tissues including the central nervous system (CNS) and preferentially damage tumors. However, such thin microbeams can only be produced by synchrotron sources and have other practical limitations to clinical implementation. To approach this problem, we first studied CNS tolerance to much thicker beams. Three of four rats whose spinal cords were exposed transaxially to four 400-Gy, 0.68-mm microbeams, spaced 4 mm, and all four rats irradiated to their brains with large, 170-Gy arrays of such beams spaced 1.36 mm, all observed for 7 months, showed no paralysis or behavioral changes. We then used an interlacing geometry in which two such arrays at a 90-degree angle produced the equivalent of a contiguous beam in the target volume only. By using this approach, we produced 90-, 120-, and 150-Gy 3.4 x 3.4 x 3.4 mm(3) exposures in the rat brain. MRIs performed 6 months later revealed focal damage within the target volume at the 120- and 150-Gy doses but no apparent damage elsewhere at 120 Gy. Monte Carlo calculations indicated a 30-microm dose falloff (80-20%) at the edge of the target, which is much less than the 2- to 5-mm value for conventional radiotherapy and radiosurgery. These findings strongly suggest potential application of interlaced microbeams to treat tumors or to ablate nontumorous abnormalities with minimal damage to surrounding normal tissue.

Citing Articles

Carbon minibeam radiation therapy results in tumor growth delay in an osteosarcoma murine model.

Bertho A, Graeff C, Ortiz R, Giorgi M, Schuy C, Juchaux M Sci Rep. 2025; 15(1):7305.

PMID: 40025099 PMC: 11873225. DOI: 10.1038/s41598-025-91872-6.


A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats.

Iturri L, Jouglar E, Gilbert C, Espenon J, Juchaux M, Prezado Y Clin Transl Radiat Oncol. 2025; 51:100911.

PMID: 39898330 PMC: 11783053. DOI: 10.1016/j.ctro.2025.100911.


Advancements and challenges in brain cancer therapeutics.

Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.

PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.


Synchrotron-based infrared microspectroscopy unveils the biomolecular response of healthy and tumour cell lines to neon minibeam radiation therapy.

Gonzalez-Vegas R, Seksek O, Bertho A, Bergs J, Hirayama R, Inaniwa T Analyst. 2024; 150(2):342-352.

PMID: 39668677 PMC: 11638702. DOI: 10.1039/d4an01038h.


Prospect of radiotherapy technology development in the era of immunotherapy.

Jin J J Natl Cancer Cent. 2024; 2(2):106-112.

PMID: 39034954 PMC: 11256706. DOI: 10.1016/j.jncc.2022.04.001.


References
1.
CURTIS H . The use of deuteron microbeam for simulating the biological effects of heavy cosmic-ray particles. Radiat Res Suppl. 1967; 7:250-7. View

2.
Miura M, Blattmann H, Brauer-Krisch E, Bravin A, Hanson A, Nawrocky M . Radiosurgical palliation of aggressive murine SCCVII squamous cell carcinomas using synchrotron-generated X-ray microbeams. Br J Radiol. 2006; 79(937):71-5. DOI: 10.1259/bjr/50464795. View

3.
Chaves A, Lopes M, Alves C, Oliveira C, Peralta L, Rodrigues P . Basic dosimetry of radiosurgery narrow beams using Monte Carlo simulations: a detailed study of depth of maximum dose. Med Phys. 2003; 30(11):2904-11. DOI: 10.1118/1.1618031. View

4.
Slatkin D, Spanne P, Dilmanian F, Sandborg M . Microbeam radiation therapy. Med Phys. 1992; 19(6):1395-400. DOI: 10.1118/1.596771. View

5.
Mack A, Wolff R, Weltz D, Mack G, Jess A, Heck B . Experimentally determined three-dimensional dose distributions in small complex targets. J Neurosurg. 2003; 97(5 Suppl):551-5. DOI: 10.3171/jns.2002.97.supplement. View